# A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer

> **NCT07000305** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tao Zhang** · enrollment: 42 (estimated)

## Conditions studied

- Advanced Colorectal Cancer

## Interventions

- **DRUG:** Cetuximabβ combined with Envolimab and mFOLFOX6

## Key facts

- **NCT ID:** NCT07000305
- **Lead sponsor:** Tao Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-20
- **Primary completion:** 2027-05-20
- **Final completion:** 2028-05-20
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07000305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07000305, "A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07000305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*